ClouDr Group Limited
智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION AGREEMENT WITH MEDICE

This announcement is made by ClouDr Group Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") on a voluntary basis. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on September 4, 2024, the Company entered into a non-legally binding strategic cooperation agreement (the "**Strategic Cooperation Agreement**") with Schaper & Brümmer GmbH & Co. KG ("**Schaper & Brümmer**"), a subsidiary of Medice Arzneimittel Pütter GmbH & Co. KG ("**Medice**") and was granted 5-year exclusive rights to import, distribute, sell and promote Remifemin® and Esberitox® in both hospitals and pharmacies in China.

Medice is a leading family-owned pharmaceutical company in Germany, with its over-the-counter and Rx brands which mainly focus on respiratory, dermatology, gut health, female health, attention deficit hyperactivity disorder (ADHD) and nephrology treatments products. Its products are leading brands in their respective fields. Schaper & Brümmer, a division of Medice's primary and consumer care segment, focuses on manufacturing and sales of high-quality herbal medicines.

The strategic cooperation between the two parties marks a significant milestone for the Company's overseas strategy, signifying that the Company has become a crucial gateway and an important partner for overseas pharmaceutical companies to access the Chinese market through its over 2,700 SaaS-installed hospitals and over 228,000 SaaS-installed pharmacies. Pursuant to the Strategic Cooperation Agreement, the Company will promote high-quality drugs of Medice to broader channels, enhance its brand value, and meet more health needs of patients with chronic conditions.

Information on Remifemin® (Imported Drug Registration Z20130001)

Remifemin® is a hormone-free herbal medicine, which is an unique isopropanolic extract from the black cohosh rootstock (rhizome). It is widely applied in the United States and Europe for the treatment of menopausal symptoms. While improving symptoms of perimenopausal syndrome, Remifemin® has no influence on hormonal parameters such as follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol and prolactin, and is safe for the target organs. Nor does it increase breast tissue density, stimulate breast epithelial cell proliferation or affect endometrium thickness.

Information on Esberitox® (Guo Yao Zhun Zi ZJ20160007)

Esberitox® is a herbal medicine which consists of four plants, i.e., purple coneflower, pale coneflower, wild indigo, and arbor vitae. It is registered in Germany and 24 other countries across the world. Clinical evidence shows that it can relieve cold symptoms and shorten the length of cold, with a high tolerability of 98.4%.

To the best of the Board's knowledge, information and belief after having made all reasonable enquiries, Medice is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The Company will comply with the Listing Rules and make further announcement(s) on the potential cooperation as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
ClouDr Group Limited
Kuang Ming
Chairman, Executive Director and Chief Executive Officer

Hong Kong, September 4, 2024

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*